Scientific Articles

Scientific articles from the DRTB-HDT consortium

Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae

Nicolas A Menzies, Matthew Quaife, Brian W Allwood, Anthony L Byrne, Anna K Coussens, Anthony D Harries, Florian M Marx, Jamilah Meghji, Debora Pedrazzoli, Joshua A Salomon, Sedona Sweeney, Sanne C van Kampen, Robert S Wallis, Rein M G J Houben, Ted Cohen,

The Lancet Global Health,
Volume 9, Issue 12, 2021

Summary: Many individuals who survive tuberculosis disease face ongoing disability and elevated mortality risks. However, the impact of post-tuberculosis sequelae is generally omitted from policy analyses and disease burden estimates. We therefore estimated the global burden of tuberculosis, inclusive of post-tuberculosis morbidity and mortality.

Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled trial

Robert S. Wallis, Sibuse Ginindza, Trevor Beattie, Nishanee Arjun, Morongwe Likoti, Modulakgotla Sebe, Vinodh A. Edward, Mohammed Rassool, Khatija Ahmed, Katherine Fielding, Bintou A. Ahidjo, Mboyo D.T. Vangu, Gavin Churchyard

PLoS ONE 17(2):

Current tuberculosis treatments leave most patients with bronchiectasis and fibrosis, permanent conditions that impair lung function and increase all-cause post-TB mortality. Host-directed therapies (HDTs) may reduce lung inflammation and hasten eradication of infection. Biomarkers can accelerate tuberculosis regimen development, but no studies have yet examined early biomarkers of TB-HDTs

Clinical standards for the assessment, management and rehabilitation of post-TB lung disease

Migliori, G. B., Marx, F. M., Ambrosino, N., Zampogna, E., Schaaf, H. S., van der Zalm, M.M., Allwood, B., Byrne A.L., Mortimer K., Wallis R.S., … Visca, D.

International Journal of Tuberculosis and Lung Disease, 25(10), 797-813


Increasing evidence suggests that post-TB lung disease (PTLD) causes significant morbidity and mortality. The aim of these clinical standards is to provide guidance on the assessment and management of PTLD and the implementation of pulmonary rehabilitation (PR). This is the first consensus-based set of Clinical Standards for PTLD. Our aim is to improve patient care and quality of life by guiding clinicians, programme managers and public health officers in planning and implementing adequate measures to assess and manage PTLD.